<table frame="void" id="inv-babdce9d-0e7f-4d0f-a77f-f2a586170424" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col id="inv-d69f6a59-c652-46ec-b4cc-bae3de58b600" width="248.00px"></col>
<col id="inv-988f736b-39cd-4f7d-a3d7-ac8b2ecd6f57" width="228.00px"></col>
<tbody id="inv-3b9dc923-a466-4f1d-8453-5697946cf2f1">
<tr id="inv-556495e9-0d67-46b2-b617-b4d9e6496aac">
<td align="center" colspan="2" id="inv-c8f4d8fc-5f63-4c34-9964-ff99689a0d72">
<content stylecode="bold">Table 1: Acyclovir Pharmacokinetic Characteristics (Range)</content>
</td>
</tr>
<tr id="inv-6611652c-28a9-4ce5-8fbf-01dfb431bf7b">
<td align="center" id="inv-4b55cb64-273f-42bc-8f0b-de65c9605a2d">
 Parameter </td>
<td align="center" id="inv-a4089c85-9de6-4906-8305-376e3c9f2e8b">
 Range </td>
</tr>
<tr id="inv-d2ecbcb7-8024-4400-892f-c3ebb968ad81">
<td align="center" id="inv-f52c4306-6a4b-46d8-bc62-fd1339220ddd">
 Plasma protein binding </td>
<td align="center" id="inv-456dee01-4f26-4f40-8ec2-77b00bbae4b2">
 9% to 33% </td>
</tr>
<tr id="inv-1f57bc0e-1694-491e-b4b1-722ab34bd9d8">
<td align="center" id="inv-160e12bd-5ff2-498d-a5a5-1de44e79a753">
 Plasma elimination half-life </td>
<td align="center" id="inv-0edc17a0-130e-4dcd-9b3b-ce946310c1a2">
 2.5 to 3.3 hr </td>
</tr>
<tr id="inv-f23c9e8b-5672-4a9f-aed0-68d13bc3920d">
<td align="center" id="inv-8d58e458-554b-4fb3-9a52-ac2030382cc6">
 Average oral bioavailability </td>
<td align="center" id="inv-6467cefc-32b2-4047-9f00-31bc8a539f0a">
 10% to 20%* </td>
</tr>
<tr id="inv-32632943-a5c1-4ca6-ae8a-2b06139240f8">
<td align="center" colspan="2" id="inv-0e318ba2-52ad-4708-abe1-355a59753dc4">
 *Bioavailability decreases with increasing dose. </td>
</tr>
</tbody>
</table>